Top

Published in:

01-03-2016 | Review Article

Tumor-associated macrophages in cancers

Authors: W. Hu, X. Li, C. Zhang, Y. Yang, J. Jiang, C. Wu

Published in: Clinical and Translational Oncology | Issue 3/2016

Abstract

Tumor-associated macrophages (TAMs) are major component of leukocytic infiltrate of tumors and play important roles in progression and regression of tumors. Tumor microenvironment determines the mutual conversion between M1 and M2 macrophages. In many kinds of tumors, M2 type macrophages are of the majority in TAMs and promote tumor progression and metastasis. The dynamic balance and interaction between TAMs and tumor cells have important effects on the occurrence and development of tumor. TAMs in malignant tumors are useful for clinical diagnosis and may provide a novel target for cancer treatment.

Murray PJ, Wynn TA. Protective and pathogenic functions of macrophage subsets. Nat Rev Immunol. 2011;11(11):723–37. doi:10.1038/nri3073.PubMedCentralCrossRefPubMed

Mantovani A, Sica A. Macrophages, innate immunity and cancer: balance, tolerance, and diversity. Curr Opin Immunol. 2010;22(2):231–7. doi:10.1016/j.coi.2010.01.009.CrossRefPubMed

Colotta F, Allavena P, Sica A, Garlanda C, Mantovani A. Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis. 2009;30(7):1073–81. doi:10.1093/carcin/bgp127.CrossRefPubMed

Biswas SK, Mantovani A. Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat Immunol. 2010;11(10):889–96. doi:10.1038/ni.1937.CrossRefPubMed

Schulz C, Gomez Perdiguero E, Chorro L, Szabo-Rogers H, Cagnard N, Kierdorf K, et al. A lineage of myeloid cells independent of Myb and hematopoietic stem cells. Science. 2012;336(6077):86–90. doi:10.1126/science.1219179.CrossRefPubMed

Gomez Perdiguero E, Geissmann F. Myb-independent macrophages: a family of cells that develops with their tissue of residence and is involved in its homeostasis. Cold Spring Harb Symp Quant Biol. 2013;78:91–100. doi:10.1101/sqb.2013.78.020032.

Sica A, Mantovani A. Macrophage plasticity and polarization: in vivo veritas. J Clin Invest. 2012;122(3):787–95. doi:10.1172/JCI59643.PubMedCentralCrossRefPubMed

Zhao H, Zhang X, Chen X, Li Y, Ke Z, Tang T, et al. Isoliquiritigenin, a flavonoid from licorice, blocks M2 macrophage polarization in colitis-associated tumorigenesis through downregulating PGE2 and IL-6. Toxicol Appl Pharmacol. 2014;279(3):311–21. doi:10.1016/j.taap.2014.07.001.CrossRefPubMed

Derlindati E, Dei Cas A, Montanini B, Spigoni V, Curella V, Aldigeri R, et al. Transcriptomic analysis of human polarized macrophages: more than one role of alternative activation? PLoS One. 2015;10(3):e0119751. doi:10.1371/journal.pone.0119751.PubMedCentralCrossRefPubMed

10.

Fagone P, Di Rosa M, Palumbo M, De Gregorio C, Nicoletti F, Malaguarnera L. Modulation of heat shock proteins during macrophage differentiation. Inflamm Res. 2012;61(10):1131–9. doi:10.1007/s00011-012-0506-y.CrossRefPubMed

11.

Josephs DH, Bax HJ, Karagiannis SN. Tumour-associated macrophage polarisation and re-education with immunotherapy. Front Biosci (Elite Ed). 2015;7:293–308.PubMed

12.

Mira E, Carmona-Rodriguez L, Tardaguila M, Azcoitia I, Gonzalez-Martin A, Almonacid L, et al. A lovastatin-elicited genetic program inhibits M2 macrophage polarization and enhances T cell infiltration into spontaneous mouse mammary tumors. Oncotarget. 2013;4(12):2288–301.PubMedCentralCrossRefPubMed

13.

Geissmann F, Manz MG, Jung S, Sieweke MH, Merad M, Ley K. Development of monocytes, macrophages, and dendritic cells. Science. 2010;327(5966):656–61. doi:10.1126/science.1178331.PubMedCentralCrossRefPubMed

14.

Li N, Qin J, Lan L, Zhang H, Liu F, Wu Z, et al. PTEN inhibits macrophage polarization from M1 to M2 through CCL2 and VEGF-A reduction and NHERF-1 synergism. Cancer Biol Ther. 2015;16(2):297–306. doi:10.1080/15384047.2014.1002353.CrossRefPubMed

15.

Allavena P, Mantovani A. Immunology in the clinic review series; focus on cancer: tumour-associated macrophages: undisputed stars of the inflammatory tumour microenvironment. Clin Exp Immunol. 2012;167(2):195–205. doi:10.1111/j.1365-2249.2011.04515.x.PubMedCentralCrossRefPubMed

16.

Ohtaki Y, Ishii G, Nagai K, Ashimine S, Kuwata T, Hishida T, et al. Stromal macrophage expressing CD204 is associated with tumor aggressiveness in lung adenocarcinoma. J Thorac Oncol. 2010;5(10):1507–15. doi:10.1097/JTO.0b013e3181eba692.CrossRefPubMed

17.

Gao X, Wang X, Yang Q, Zhao X, Wen W, Li G, et al. Tumoral expression of IL-33 inhibits tumor growth and modifies the tumor microenvironment through CD8⁺ T and NK cells. J Immunol. 2015;194(1):438–45. doi:10.4049/jimmunol.1401344.PubMedCentralCrossRefPubMed

18.

Gensel JC, Zhang B. Macrophage activation and its role in repair and pathology after spinal cord injury. Brain Res. 2015;. doi:10.1016/j.brainres.2014.12.045.PubMed

19.

Solinas G, Germano G, Mantovani A, Allavena P. Tumor-associated macrophages (TAM) as major players of the cancer-related inflammation. J Leukoc Biol. 2009;86(5):1065–73. doi:10.1189/jlb.0609385.CrossRefPubMed

20.

Hagemann T, Wilson J, Burke F, Kulbe H, Li NF, Pluddemann A, et al. Ovarian cancer cells polarize macrophages toward a tumor-associated phenotype. J immunol. 2006;176(8):5023–32.CrossRefPubMed

21.

Allavena P, Chieppa M, Bianchi G, Solinas G, Fabbri M, Laskarin G, et al. Engagement of the mannose receptor by tumoral mucins activates an immune suppressive phenotype in human tumor-associated macrophages. Clin Dev Immunol. 2010;2010:547179. doi:10.1155/2010/547179.PubMedCentralCrossRefPubMed

22.

Mantovani A, Allavena P. The interaction of anticancer therapies with tumor-associated macrophages. J Exp Med. 2015;. doi:10.1084/jem.20150295.

23.

Qian BZ, Pollard JW. Macrophage diversity enhances tumor progression and metastasis. Cell. 2010;141(1):39–51. doi:10.1016/j.cell.2010.03.014.CrossRefPubMed

24.

Jung KY, Cho SW, Kim YA, Kim D, Oh BC, Park DJ, et al. Cancers with higher density of tumor-associated macrophages were associated with poor survival rates. J Pathol Transl Med. 2015;. doi:10.4132/jptm.2015.06.01.

25.

Kang FB, Wang L, Li D, Zhang YG, Sun DX. Hepatocellular carcinomas promote tumor-associated macrophage M2-polarization via increased B7-H3 expression. Oncol Rep. 2015;33(1):274–82. doi:10.3892/or.2014.3587.PubMed

26.

Wan S, Zhao E, Kryczek I, Vatan L, Sadovskaya A, Ludema G, et al. Tumor-associated macrophages produce interleukin 6 and signal via STAT3 to promote expansion of human hepatocellular carcinoma stem cells. Gastroenterology. 2014;147(6):1393–404. doi:10.1053/j.gastro.2014.08.039.PubMedCentralCrossRefPubMed

27.

Kang FB, Wang L, Jia HC, Li D, Li HJ, Zhang YG, et al. B7-H3 promotes aggression and invasion of hepatocellular carcinoma by targeting epithelial-to-mesenchymal transition via JAK2/STAT3/Slug signaling pathway. Cancer Cell Int. 2015;15:45. doi:10.1186/s12935-015-0195-z.PubMedCentralCrossRefPubMed

28.

Olmeda D, Jorda M, Peinado H, Fabra A, Cano A. Snail silencing effectively suppresses tumour growth and invasiveness. Oncogene. 2007;26(13):1862–74. doi:10.1038/sj.onc.1209997.CrossRefPubMed

29.

Amizadeh M, Shamsadini A, Arabzadeh A, Jazayeri S. Association of cagA positive Helicobacter pylori infection and laryngeal squamous cell carcinoma: a pcr approach. Indian J Otolaryngol Head Neck Surg. 2015;67(Suppl 1):51–5. doi:10.1007/s12070-014-0750-2.CrossRefPubMed

30.

Waldum HL, Hauso O, Sordal OF, Fossmark R. Gastrin may mediate the carcinogenic effect of Helicobacter pylori infection of the stomach. Dig Dis Sci. 2014;. doi:10.1007/s10620-014-3468-9.PubMed

31.

Uemura N, Okamoto S, Yamamoto S, Matsumura N, Yamaguchi S, Yamakido M, et al. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med. 2001;345(11):784–9. doi:10.1056/NEJMoa001999.CrossRefPubMed

32.

Quiding-Jarbrink M, Raghavan S, Sundquist M. Enhanced M1 macrophage polarization in human helicobacter pylori-associated atrophic gastritis and in vaccinated mice. PLoS One. 2010;5(11):e15018. doi:10.1371/journal.pone.0015018.PubMedCentralCrossRefPubMed

33.

Hu CT, Guo LL, Feng N, Zhang L, Zhou N, Ma LL, et al. MIF, secreted by human hepatic sinusoidal endothelial cells, promotes chemotaxis and outgrowth of colorectal cancer in liver prometastasis. Oncotarget. 2015 [Epub ahead of print].

34.

Ou Y, Kang M, Zhou L, Cheng Z, Tang S, Yu D. Infection with L-form of Helicobacter pylori and expressions of MIF, MMP9 and VEGF in gastric carcinoma. Nan Fang Yi Ke Da Xue Xue Bao. 2014;34(2):180–7.PubMed

35.

Bonapace L, Coissieux MM, Wyckoff J, Mertz KD, Varga Z, Junt T, et al. Cessation of CCL2 inhibition accelerates breast cancer metastasis by promoting angiogenesis. Nature. 2014;515(7525):130–3. doi:10.1038/nature13862.CrossRefPubMed

36.

Dokduang H, Techasen A, Namwat N, Khuntikeo N, Pairojkul C, Murakami Y, et al. STATs profiling reveals predominantly-activated STAT3 in cholangiocarcinoma genesis and progression. J Hepato-Biliary-Pancreat Sci. 2014;21(10):767–76. doi:10.1002/jhbp.131.CrossRef

37.

Zheng D, Wang Y, Cao Q, Lee VW, Zheng G, Sun Y, et al. Transfused macrophages ameliorate pancreatic and renal injury in murine diabetes mellitus. Nephron Exp Nephrol. 2011;118(4):e87–99. doi:10.1159/000321034.CrossRefPubMed

38.

Koscso B, Csoka B, Kokai E, Nemeth ZH, Pacher P, Virag L, et al. Adenosine augments IL-10-induced STAT3 signaling in M2c macrophages. J Leukoc Biol. 2013;94(6):1309–15. doi:10.1189/jlb.0113043.PubMedCentralCrossRefPubMed

39.

Vlaicu P, Mertins P, Mayr T, Widschwendter P, Ataseven B, Hogel B, et al. Monocytes/macrophages support mammary tumor invasivity by co-secreting lineage-specific EGFR ligands and a STAT3 activator. BMC Cancer. 2013;13:197. doi:10.1186/1471-2407-13-197.PubMedCentralCrossRefPubMed

40.

Yang C, He L, He P, Liu Y, Wang W, He Y, et al. Increased drug resistance in breast cancer by tumor-associated macrophages through IL-10/STAT3/bcl-2 signaling pathway. Med Oncol. 2015;32(2):352. doi:10.1007/s12032-014-0352-6.CrossRefPubMed

41.

Qian BZ, Li J, Zhang H, Kitamura T, Zhang J, Campion LR, et al. CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis. Nature. 2011;475(7355):222–5. doi:10.1038/nature10138.PubMedCentralCrossRefPubMed

42.

Lu X, Kang Y. Chemokine (C-C motif) ligand 2 engages CCR2⁺ stromal cells of monocytic origin to promote breast cancer metastasis to lung and bone. J Biol Chem. 2009;284(42):29087–96. doi:10.1074/jbc.M109.035899.PubMedCentralCrossRefPubMed

43.

Wolf MJ, Hoos A, Bauer J, Boettcher S, Knust M, Weber A, et al. Endothelial CCR2 signaling induced by colon carcinoma cells enables extravasation via the JAK2-Stat5 and p38MAPK pathway. Cancer Cell. 2012;22(1):91–105. doi:10.1016/j.ccr.2012.05.023.CrossRefPubMed

44.

Wu M, Shao GR, Zhang FX, Wu WX, Xu P, Ruan ZM. Legumain protein as a potential predictive biomarker for asian patients with breast carcinoma. Asian Pac J Cancer Prev. 2014;15(24):10773–7.CrossRefPubMed

45.

D’Costa ZC, Higgins C, Ong CW, Irwin GW, Boyle D, McArt DG, et al. TBX2 represses CST6 resulting in uncontrolled legumain activity to sustain breast cancer proliferation: a novel cancer-selective target pathway with therapeutic opportunities. Oncotarget. 2014;5(6):1609–20.PubMedCentralCrossRefPubMed

46.

Luo Y, Zhou H, Krueger J, Kaplan C, Lee SH, Dolman C, et al. Targeting tumor-associated macrophages as a novel strategy against breast cancer. J Clin Invest. 2006;116(8):2132–41. doi:10.1172/JCI27648.PubMedCentralCrossRefPubMed

47.

Hagemann T, Balkwill F, Lawrence T. Inflammation and cancer: a double-edged sword. Cancer Cell. 2007;12(4):300–1. doi:10.1016/j.ccr.2007.10.005.PubMedCentralCrossRefPubMed

48.

Kee JY, Ito A, Hojo S, Hashimoto I, Igarashi Y, Tsukada K, et al. Chemokine CXCL16 suppresses liver metastasis of colorectal cancer via augmentation of tumor-infiltrating natural killer T cells in a murine model. Oncol Rep. 2013;29(3):975–82. doi:10.3892/or.2012.2185.PubMed

49.

Kee JY, Ito A, Hojo S, Hashimoto I, Igarashi Y, Tsuneyama K, et al. CXCL16 suppresses liver metastasis of colorectal cancer by promoting TNF-alpha-induced apoptosis by tumor-associated macrophages. BMC Cancer. 2014;14:949. doi:10.1186/1471-2407-14-949.PubMedCentralCrossRefPubMed

50.

Kaler P, Galea V, Augenlicht L, Klampfer L. Tumor associated macrophages protect colon cancer cells from TRAIL-induced apoptosis through IL-1beta-dependent stabilization of Snail in tumor cells. PLoS One. 2010;5(7):e11700. doi:10.1371/journal.pone.0011700.PubMedCentralCrossRefPubMed

51.

Illemann M, Laerum OD, Hasselby JP, Thurison T, Hoyer-Hansen G, Nielsen HJ, et al. Urokinase-type plasminogen activator receptor (uPAR) on tumor-associated macrophages is a marker of poor prognosis in colorectal cancer. Cancer Med. 2014;3(4):855–64. doi:10.1002/cam4.242.PubMedCentralCrossRefPubMed

52.

Blok DC, Kager LM, Hoogendijk AJ, Lede IO, Rahman W, Afroz R, et al. Expression of inhibitory regulators of innate immunity in patients with active tuberculosis. BMC Infect Dis. 2015;15(1):98. doi:10.1186/s12879-015-0833-z.PubMedCentralCrossRefPubMed

53.

Kim DW, Min HS, Lee KH, Kim YJ, Oh DY, Jeon YK, et al. High tumour islet macrophage infiltration correlates with improved patient survival but not with EGFR mutations, gene copy number or protein expression in resected non-small cell lung cancer. Br J Cancer. 2008;98(6):1118–24. doi:10.1038/sj.bjc.6604256.PubMedCentralCrossRefPubMed

54.

Welsh TJ, Green RH, Richardson D, Waller DA, O’Byrne KJ, Bradding P. Macrophage and mast-cell invasion of tumor cell islets confers a marked survival advantage in non-small-cell lung cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2005;23(35):8959–67. doi:10.1200/JCO.2005.01.4910.CrossRef

55.

Gillard-Bocquet M, Caer C, Cagnard N, Crozet L, Perez M, Fridman WH, et al. Lung tumor microenvironment induces specific gene expression signature in intratumoral NK cells. Front Immunol. 2013;4:19. doi:10.3389/fimmu.2013.00019.PubMedCentralCrossRefPubMed

56.

Schmall A, Al-Tamari HM, Herold S, Kampschulte M, Weigert A, Wietelmann A, et al. Macrophage and cancer cell cross-talk via CCR2 and CX3CR1 is a fundamental mechanism driving lung cancer. Am J Respir Crit Care Med. 2015;191(4):437–47. doi:10.1164/rccm.201406-1137OC.CrossRefPubMed

57.

Fritz JM, Tennis MA, Orlicky DJ, Lin H, Ju C, Redente EF, et al. Depletion of tumor-associated macrophages slows the growth of chemically induced mouse lung adenocarcinomas. Front Immunol. 2014;5:587. doi:10.3389/fimmu.2014.00587.PubMedCentralCrossRefPubMed

58.

Shigeoka M, Urakawa N, Nakamura T, Nishio M, Watajima T, Kuroda D, et al. Tumor associated macrophage expressing CD204 is associated with tumor aggressiveness of esophageal squamous cell carcinoma. Cancer Sci. 2013;104(8):1112–9. doi:10.1111/cas.12188.CrossRefPubMed

59.

Shigeoka M, Urakawa N, Nishio M, Takase N, Utsunomiya S, Akiyama H, et al. Cyr61 promotes CD204 expression and the migration of macrophages via MEK/ERK pathway in esophageal squamous cell carcinoma. Cancer Med. 2015;. doi:10.1002/cam4.401.PubMedCentralPubMed

60.

Chen SJ, Zhang QB, Zeng LJ, Lian GD, Li JJ, Qian CC, et al. Distribution and clinical significance of tumour-associated macrophages in pancreatic ductal adenocarcinoma: a retrospective analysis in China. Curr Oncol. 2015;22(1):e11–9. doi:10.3747/co.22.2150.PubMedCentralCrossRefPubMed

61.

Meng F, Li C, Li W, Gao Z, Guo K, Song S. Interaction between pancreatic cancer cells and tumor-associated macrophages promotes the invasion of pancreatic cancer cells and the differentiation and migration of macrophages. IUBMB Life. 2014;66(12):835–46. doi:10.1002/iub.1336.CrossRefPubMed

62.

Karnevi E, Andersson R, Rosendahl AH. Tumour-educated macrophages display a mixed polarisation and enhance pancreatic cancer cell invasion. Immunol Cell Biol. 2014;92(6):543–52. doi:10.1038/icb.2014.22.CrossRefPubMed

63.

Sugimoto M, Mitsunaga S, Yoshikawa K, Kato Y, Gotohda N, Takahashi S, et al. Prognostic impact of M2 macrophages at neural invasion in patients with invasive ductal carcinoma of the pancreas. Eur J Cancer. 2014;50(11):1900–8. doi:10.1016/j.ejca.2014.04.010.CrossRefPubMed

64.

Hermano E, Meirovitz A, Meir K, Nussbaum G, Appelbaum L, Peretz T, et al. Macrophage polarization in pancreatic carcinoma: role of heparanase enzyme. J Natl Cancer Inst. 2014;106(12). doi:10.1093/jnci/dju332.

65.

Hou YC, Chao YJ, Tung HL, Wang HC, Shan YS. Coexpression of CD44-positive/CD133-positive cancer stem cells and CD204-positive tumor-associated macrophages is a predictor of survival in pancreatic ductal adenocarcinoma. Cancer. 2014;120(17):2766–77. doi:10.1002/cncr.28774.CrossRefPubMed

66.

He YF, Zhang MY, Wu X, Sun XJ, Xu T, He QZ, et al. High MUC2 expression in ovarian cancer is inversely associated with the M1/M2 ratio of tumor-associated macrophages and patient survival time. PLoS One. 2013;8(12):e79769. doi:10.1371/journal.pone.0079769.PubMedCentralCrossRefPubMed

67.

Armaiz-Pena GN, Gonzalez-Villasana V, Nagaraja AS, Rodriguez-Aguayo C, Sadaoui NC, Stone RL, et al. Adrenergic regulation of monocyte chemotactic protein 1 leads to enhanced macrophage recruitment and ovarian carcinoma growth. Oncotarget. 2014 [Epub ahead of print].

68.

Ko SY, Ladanyi A, Lengyel E, Naora H. Expression of the homeobox gene HOXA9 in ovarian cancer induces peritoneal macrophages to acquire an M2 tumor-promoting phenotype. Am J Pathol. 2014;184(1):271–81. doi:10.1016/j.ajpath.2013.09.017.PubMedCentralCrossRefPubMed

69.

Zhang M, He Y, Sun X, Li Q, Wang W, Zhao A, et al. A high M1/M2 ratio of tumor-associated macrophages is associated with extended survival in ovarian cancer patients. J Ovarian Res. 2014;7:19. doi:10.1186/1757-2215-7-19.PubMedCentralCrossRefPubMed

70.

Dossett LA, Kudchadkar RR, Zager JS. BRAF and MEK inhibition in melanoma. Expert Opin Drug Saf. 2015;14(4):559–70.CrossRefPubMed

71.

Wang T, Xiao M, Ge Y, Krepler C, Belser E, Lopez-Coral A, et al. BRAF inhibition stimulates melanoma-associated macrophages to drive tumor growth. Clin Cancer Res. 2015;. doi:10.1158/1078-0432.CCR-14-1554.

72.

Tham M, Tan KW, Keeble J, Wang X, Hubert S, Barron L, et al. Melanoma-initiating cells exploit M2 macrophage TGFbeta and arginase pathway for survival and proliferation. Oncotarget. 2014;5(23):12027–42.PubMedCentralCrossRefPubMed

73.

Ding H, Cai J, Mao M, Fang Y, Huang Z, Jia J, et al. Tumor-associated macrophages induce lymphangiogenesis in cervical cancer via interaction with tumor cells. APMIS. 2014;122(11):1059–69. doi:10.1111/apm.12257.PubMed

74.

Strachan DC, Ruffell B, Oei Y, Bissell MJ, Coussens LM, Pryer N, et al. CSF1R inhibition delays cervical and mammary tumor growth in murine models by attenuating the turnover of tumor-associated macrophages and enhancing infiltration by CD8 T cells. Oncoimmunology. 2013;2(12):e26968. doi:10.4161/onci.26968.PubMedCentralCrossRefPubMed

75.

Dijkgraaf EM, Heusinkveld M, Tummers B, Vogelpoel LT, Goedemans R, Jha V, et al. Chemotherapy alters monocyte differentiation to favor generation of cancer-supporting M2 macrophages in the tumor microenvironment. Cancer Res. 2013;73(8):2480–92. doi:10.1158/0008-5472.CAN-12-3542.CrossRefPubMed

76.

Sica A, Larghi P, Mancino A, Rubino L, Porta C, Totaro MG, et al. Macrophage polarization in tumour progression. Semin Cancer Biol. 2008;18(5):349–55. doi:10.1016/j.semcancer.2008.03.004.CrossRefPubMed

77.

Sica A, Schioppa T, Mantovani A, Allavena P. Tumour-associated macrophages are a distinct M2 polarised population promoting tumour progression: potential targets of anti-cancer therapy. Eur J Cancer. 2006;42(6):717–27. doi:10.1016/j.ejca.2006.01.003.CrossRefPubMed

78.

Wu Y, Deng J, Rychahou PG, Qiu S, Evers BM, Zhou BP. Stabilization of snail by NF-kappaB is required for inflammation-induced cell migration and invasion. Cancer Cell. 2009;15(5):416–28. doi:10.1016/j.ccr.2009.03.016.PubMedCentralCrossRefPubMed

Title: Tumor-associated macrophages in cancers
Authors: W. Hu
X. Li
C. Zhang
Y. Yang
J. Jiang
C. Wu
Publication date: 01-03-2016
Publisher: Springer Milan
Published in: Clinical and Translational Oncology / Issue 3/2016
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI: https://doi.org/10.1007/s12094-015-1373-0

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2016

The expression and function of Frizzled-7 in human renal cell carcinoma

Stereotactic body radiotherapy (SBRT) for the treatment of inoperable stage I non-small cell lung cancer patients

Central nervous system niche involvement in the leukemia

Prognostic factors affecting survival in metastatic soft tissue sarcoma: an analysis of 110 patients

The role of human epididymis protein 4 in the diagnosis of epithelial ovarian cancer

XIAP inhibitor Embelin inhibits bladder cancer survival and invasion in vitro

Keynote webinar | Spotlight on antibody–drug conjugates in cancer